UNSPSC 51181926: Buserelin acetate

This classification denotes the acetate form of a gonadotropin-releasing hormone analog with the molecular formula C60H86N16O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PXW8U3YXDV, chemically known as luteinizing hormone-releasing hormone (pig), 6-(o-(1,1-dimethylethyl)-d-serine)-9-(n-ethyl-l-prolinamide)-10-deglycinamide- but more generally known as buserelin, which bears US NIH Compound Identifier 42615. Buserelin most often comes in base and acetate forms.

UNSPSC 51181926 Buserelin acetate is a Commodity code covering a specific injectable pharmaceutical used in endocrinology and oncology applications. State and local government purchases under this code are driven primarily by cooperative purchasing alliances that aggregate demand across multiple jurisdictions to negotiate volume pricing with pharmaceutical manufacturers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing model for this category — soliciting manufacturers to supply generic and branded pharmaceuticals through established wholesale distribution networks. Participating jurisdictions access agreed pricing via authorized distributors rather than purchasing directly, which concentrates procurement activity around multi-state cooperative vehicles and the state procurement offices that administer them. State health departments, Medicaid programs, corrections systems, and other state-operated health facilities drive demand for this commodity, with cooperative purchasing structures enabling smaller local governments and school districts to access negotiated rates.

MMCAP issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with responses due March 26, 2026. The solicitation covers Minnesota and Oregon, requiring manufacturers to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and to comply with cGMP certification, DSCSA compliance, and FDA requirements. Pricing is weighted at 75 percent of the evaluation, with suppliers required to maintain the product on the market with at least one year expiration dating and six-month shelf life from manufacture. The contract term runs two years from an effective date of July 1, 2026, with optional extensions at MMCAP's discretion. No specific set-aside designations are identified in the documentation, and no award value is disclosed; vendors pay a 3 percent administrative fee on all contract purchases and face performance penalties ranging from $200 to $1,500 per violation.